NASDAQ:VERA Vera Therapeutics (VERA) Stock Price, News & Analysis $35.05 +1.45 (+4.32%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$34.80 -0.25 (-0.70%) As of 09/11/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vera Therapeutics Stock (NASDAQ:VERA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vera Therapeutics alerts:Sign Up Key Stats Today's Range$33.75▼$35.2950-Day Range$28.89▼$43.1352-Week Range$22.72▼$56.05Volume3.80 million shsAverage Volume1.95 million shsMarket Capitalization$2.53 billionP/E RatioN/ADividend YieldN/APrice Target$80.15Consensus RatingModerate Buy Company Overview Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms. Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand. The company is evaluating atacicept primarily as a potential treatment for IgA nephropathy, a chronic autoimmune kidney disease, in the global Phase 3 ORIGIN clinical trial. Vera Therapeutics is headquartered in the San Francisco Bay Area and conducts development activities and clinical studies through sites in the United States and other international markets. As a clinical-stage company, Vera does not currently have an approved commercial product; its business is focused on research, clinical development and potential regulatory approval of therapies for patients with serious immune-mediated diseases.AI Generated. May Contain Errors. Read More Vera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreVERA MarketRank™: Vera Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 445th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingVera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVera Therapeutics has a consensus price target of $80.15, representing about 128.7% upside from its current price of $35.05.Amount of Analyst CoverageVera Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vera Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vera Therapeutics are expected to grow in the coming year, from ($6.44) to ($4.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vera Therapeutics is -5.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vera Therapeutics is -5.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVera Therapeutics has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vera Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted32.79% of the float of Vera Therapeutics has been sold short.Short Interest Ratio / Days to CoverVera Therapeutics has a short interest ratio ("days to cover") of 10.81, which indicates bearish sentiment.Change versus previous monthShort interest in Vera Therapeutics has recently increased by 18.19%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVera Therapeutics does not currently pay a dividend.Dividend GrowthVera Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.81 News SentimentVera Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Vera Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,307,800.00 in company stock.Percentage Held by Insiders15.90% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vera Therapeutics' insider trading history. Receive VERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VERA Stock News HeadlinesJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Vera Therapeutics (NASDAQ:VERA) StockSeptember 10 at 1:24 AM | americanbankingnews.comInsider Selling: Vera Therapeutics (NASDAQ:VERA) CEO Sells $649,720.00 in StockSeptember 7, 2026 | americanbankingnews.comIt’s not about GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar. | Porter & Company (Ad)Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comVera Therapeutics to Participate at Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comVera Therapeutics, Inc. (VERA) Stock Price, News, Quote & History - Yahoo FinanceAugust 25, 2026 | finance.yahoo.comJ.P. Morgan Sticks to Their Buy Rating for Vera Therapeutics (VERA)August 19, 2026 | theglobeandmail.comVera Therapeutics: FDA's eGFR Analysis Supports A Speculative BuyAugust 17, 2026 | seekingalpha.comSee More Headlines VERA Stock Analysis - Frequently Asked Questions How have VERA shares performed this year? Vera Therapeutics' stock was trading at $50.64 at the beginning of the year. Since then, VERA shares have decreased by 30.8% and is now trading at $35.05. How were Vera Therapeutics' earnings last quarter? Vera Therapeutics, Inc. (NASDAQ:VERA) released its earnings results on Monday, August, 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.58) by $0.06. When did Vera Therapeutics IPO? Vera Therapeutics (VERA) raised $65 million in an initial public offering on Thursday, May 13th 2021. The company issued 4,350,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO. Who are Vera Therapeutics' major shareholders? Top institutional investors of Vera Therapeutics include California State Teachers Retirement System (2.88%), Braidwell LP (0.78%), Readystate Asset Management LP (0.41%) and Engineers Gate Manager LP (0.15%). Insiders that own company stock include Commodore Capital Lp, Maha Katabi, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Laurence Matthew Skelton, Robert Brenner, David Lee Johnson, William D Turner and Patrick G Enright. View institutional ownership trends. How do I buy shares of Vera Therapeutics? Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings8/10/2026Today9/11/2026Morgan Stanley 24th Annual Global Healthcare Conference9/15/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VERA's financial health is in the Yellow zone, according to TradeSmith. VERA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VERA CIK1831828 Webveratx.com Phone650-770-0077FaxN/AEmployees361Year Founded2016Price Target and Rating Average Price Target for Vera Therapeutics$80.15 High Price Target$125.00 Low Price Target$34.00 Potential Upside/Downside+128.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($5.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$299.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-84.13% Return on Assets-66.79% Debt Debt-to-Equity Ratio0.18 Current Ratio10.92 Quick Ratio10.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.48 per share Price / Book4.13Miscellaneous Outstanding Shares72,063,000Free Float60,605,000Market Cap$2.53 billion OptionableOptionable Beta0.96 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:VERA) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThis metric called 1929, 1969 and 2000 [it's screaming now]The Buffett Indicator once flagged the 1929, 1969, and 2000 market peaks - and it's now at 231%, its highest r...Golden Portfolio | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe retirement income that answers “yes” when everything else says noTodd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...Eagle Publishing | SponsoredElon’s “nude” scandal – a big opportunity?Louis Navellier, the quantitative analyst who called Nvidia before its 44,000% run, says Elon Musk's AI ambiti...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VERA with Qtrade Free VERA Stock Alerts